Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00367211 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

A Phase 3 study, sponsored by POZEN.

Completed
Registry status
Phase 3
Development phase
400
Enrollment target

NCT00367211 is a Phase 3 study that has completed, run by POZEN. The registered enrollment target is 400 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00367211, a Phase 3 study, has completed, sponsored by POZEN.

COMPLETED
Registry status
Phase 3
Development phase
400 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the incidence of gastric ulcers following administration of either PN 200 or Naproxen in subjects who are at risk for developing NSAID-associated ulcers.

Interventions

  • DRUG PN 200 tablets (500 mg naproxen and 20 mg omeprazole)
  • DRUG Naproxen 500 mg tablets (PN 200 minus omeprazole)

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2006-09
Est. Completion 2007-09
Phase Phase 3

Sponsor

POZEN

24 total trials

What the Registry Record Tells You About NCT00367211

The ClinicalTrials.gov registry entry for NCT00367211 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POZEN, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which PN 200 tablets (500 mg naproxen and 20 mg omeprazole) is the first listed.

NCT00367211 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00367211 about?

NCT00367211 is a clinical study titled "Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.". The purpose of this study is to evaluate the incidence of gastric ulcers following administration of either PN 200 or Naproxen in subjects who are at risk for developing NSAID-associated ulcers.

What is the current status of trial NCT00367211?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2006-09. Estimated completion is 2007-09.

What interventions are being tested in trial NCT00367211?

The interventions under investigation include: PN 200 tablets (500 mg naproxen and 20 mg omeprazole) (DRUG), Naproxen 500 mg tablets (PN 200 minus omeprazole) (DRUG).

Who is sponsoring clinical trial NCT00367211?

This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.